Strides Pharma Science announced that it has received Emergency Use Authorization from the Drugs Controller General of India (DCGI) to launch molnupiravir 200mg in India. Molnupiravir is an orally administered form of a potent ribonucleoside analog that inhibits the replication of SARS-CoV-2 and the clinical studies have shown this drug to be active against the most common Covid-19 variants.

Under the brand name Stripiravir, Strides has developed molnupiravir and is commercializing the product with a group integrated supply chain for Active Pharmaceutical Ingredients and solid oral dosage from its large-scale WHO Pre-Qualified (PQ) manufacturing capacities.

Dr. R Ananthanarayanan, Managing Director & Chief Executive Officer, Strides Pharma Science said "We are delighted to receive the DCGI approval for launching molnupiravir, which has shown promising results in several clinical studies. The product provides therapeutic benefit to the patients with mild to moderate Covid symptoms and can be administered at home. With the emergence of the new variants, we believe molnupiravir will benefit the broad population which could be at risk due to Covid-19. We remain committed in our fight against this global pandemic."